Smoking, Cigarette
Conditions
Keywords
Staccato Loxapine, pharmacokinetics, smokers, non-smokers
Brief summary
The objective of this trial was to assess the pharmacokinetics of a single dose of 10 mg Staccato Loxapine administered to smokers compared to nonsmokers.
Detailed description
Pharmacokinetics and sedation pharmacodynamics were studied using a visual analog scale were studied in male and female adult subjects (nonsmokers and smokers) following a single dose of 10 mg of inhaled loxapine. Blood samples were drawn at predose, 30 seconds, 1, 2, 3, 10, 30, and 60 minutes, and 2, 6, 12, and 24 hours after dosing. Loxapine and 8-OH-loxapine were analyzed using reverse-phase liquid chromatography coupled with a tandem mass spectrometer.
Interventions
Staccato Loxapine 10 mg, single dose
Sponsors
Alexza Pharmaceuticals, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
Single-center, single-dose, single-treatment, open label study
Eligibility
Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Normal spirometry at screening and in good general health as determined by a complete medical history, physical examination, 12-lead ECG, blood chemistry profile, hematology, and urinalysis, * Smokers must have a history of smoking \> 15 cigarettes/day currently and for at least the last 2 years, * Nonsmokers must have never smoked \> 5 cigarettes/day and not smoking at all for at least the last 2 years.
Exclusion criteria
* Any acute illness in the 5 days, * Use of a bronchodilator for the treatment of wheezing within 12 months, OR * Any other disease or condition, by history, physical examination, or laboratory abnormalities that would present undue risk to the subject, or may confound the interpretation of study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Noncompartmental Pharmacokinetic parameters | 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| Vital signs | 24 hours |
| Treatment emergent adverse events | 24 hours |
| Sedation visual analog scale | 24 hours |
Countries
United States
Outcome results
None listed